will be the second clinical candidate to receive Formatech
services under its Fillanthropy program
. Under this program, Formatech will donate the services required to aseptically fill and finish one lot of the drug product for use in support of KAI’s upcoming clinical trials.
KAI-4169 is being evaluated for use in the treatment of secondary hyperparathyroidism (SHPT) in kidney disease patients. Formatech plans to complete the production run of KAI-4169 in the first quarter of 2010.